First ALS Patient Enrolled in Phase 2b Study of NeuroSense’s PrimeC

A Phase 2b clinical trial evaluating NeuroSense Therapeutics’ experimental combination therapy PrimeC in people with amyotrophic lateral sclerosis (ALS) has enrolled its first patient. PARADIGM (NCT05357950) is the company’s next step following the completion of a Phase 2a trial (NCT04165850) wherein the therapy effectively slowed disease…

Stealth BioTherapeutics’ investigational therapy SBT-272 eased inflammation and upper motor neuron degeneration in a mouse model of amyotrophic lateral sclerosis (ALS) associated with the accumulation of toxic TDP-43 protein clumps, the company announced. Motor neurons are nerve cells that control voluntary movement and progressively die in people with ALS.

A new study is investigating the longer-term effects — over a one-year period — of the therapy candidate reldesemtiv in people with amyotrophic lateral sclerosis (ALS). Cytokinetics has launched an open-label extension (OLE) study to evaluate the safety and effectiveness of reldesemtiv over a longer course in patients…

Treatment with ultrahigh-dose methylcobalamin — the physiologically active form of vitamin B12 — effectively slowed functional decline in people with early-stage amyotrophic lateral sclerosis (ALS) and moderate progression, data from a small Phase 3 trial in Japan show. The findings confirm previous results from a Phase 2/3 trial and…

“Kristin, if you can’t choose joy for yourself, then do it so Todd’s remaining days and years won’t be miserable,” I wrote in my journal a month after my husband, Todd, was diagnosed with ALS. “Do it so your kids can see how to live well, so they…

Note: This story was updated June 16, 2022, to reflect that competitor Kyle Brown was not disqualified, but did not finish the swim portion of the Ironman World Championship within the time limit and was not able to move forward in the competition.   Patrick Harfield was on his last legs.

The Greater Chicago Chapter of the ALS Association is in high gear to end amyotrophic lateral sclerosis (ALS), with multiple awareness and fundraising events taking place throughout June and July. On June 4, after two years of walking in their respective neighborhoods, supporters returned to Cantigny Park in…

Ever since I was diagnosed with ALS in 2010, I’ve become sensitive to how ALS is represented in the movies. And I’ll admit to voicing my opinion about the topic in several of my past columns. So you can imagine my glee and pride when, six months…

Radicava ORS, an oral formulation of edaravone recently approved to treat amyotrophic lateral sclerosis (ALS) in the U.S., was safe and generally well-tolerated over almost a year of treatment in a Phase 3 clinical trial, new data highlight. The results were presented by the therapy’s developer, Mitsubishi Tanabe…

Albrioza, formerly called AMX0035, has been given conditional approval by Health Canada for the treatment of amyotrophic lateral sclerosis (ALS). The decision marks a first approval for Albrioza by a regulatory authority in any country and the first new ALS therapy to enter the Canadian market since 2018.